Going to close out/ignore all the chums, and the new non-chum chum polemic polemandick who is dumb, jealous, and the PeeWee Herman Schick old and no good. t
One outside risk for GILD that would make someone worried and might make not all that aggressive would be if they are found to have willfully violated those two patents they could get triple damages from whatever the court finds to be appropriate. Maybe some news by Tuesday. r
You're trying to divert attention away from your cocky call on PTLA. Thought you were getting more modest but I guess not. You are smarter than the polemandick but still on ignore. t
Didn't switch to ignore and have more respect for you with your guts and recommendations. The polemandcik would tell you about the python.......man, what a wrong match biotech and him!!!! Some maybe more back things going on with the ALNY lover affair than the python knows. t
Again the clinical data continues to impress albeit early data vs. compared to later data but still good. The down day was not on unusually high volume and someone was maybe moving out of this investment for other reasons. In any case, it wasn't down because of bad news IMO. t
A judge this time making the assessment of possible royalty payments. A bigger than 3.5% payout for US revenue would surprise wall street. The judge very well could do that to make amends for the very low judgement given by a jury that was headed up by a twenty year old. The other thing that GILD has to watch out for is if the unclean hands argument doesn't hold water and they are found to have wllfully neglected their patent responsibility payments they could suffer triple penalty expenses on top of whatever is settled upon. t
A classic, but with that brain washing course that they all have to pass to be chum. The other none chum chum gets under the rules by qualifying by having only a seven word vocabulary. t
Surprised his captors allow a sex offended to do this. t
I've seen this bozo make ethnic remarks to this guy on the ALNY board who had an Italian surname. All the while the other called things as they really were. No knowledge, everything sexual, nothing to offer. IQ is three times his seven word vocabulary. This MB is already compromised with low quality people like him....but he is the worst. Urge that he be flagged for abuse and hopefully he can get some help. t
I don't think Pear is the enemy. He is just posting a timing opinion. In regards to competitor update we need to look further into EXEL as they came out with fairly good data today. I'll look into it further over the next day. t
IMO it is noise put out by GILD. It shouldn't change the outcome. MRK/IONS already got penalized by having that young head juror and misinformed jury where they were lead to believe that the price paid for Pharasset was an expense in developing and making the drug and counted that $11 billion purchase price of Pharmasset as an expense....really unheard of. They guy from MTSL is saying look for a 4-7% settlement on royalties. Of course GILD will look for an appeal. t
He bet heavily on ALNY's success. He would attack anyone incessantly if they said anything bad about ALNY. He was defending it at $140 and all the way down. Because he thinks he knows about RNA technology he has shorted IONS heavily as a way to get his lost money back. He will lose again. t
There could very well be four phase IIII drugs to be reported on by the first half of 2017):
expected timeline for reporting top-line results from Phase 3 EPIC registration clinical trial of Plazomicin; expects completion of enrollment in Phase 3 EPIC study in 2016, top-line data in 1Q17 and NDA Submission in 2H17 (2.74)
Co announced the acceleration of the expected timeline for reporting results from the Company's ongoing Phase 3 EPIC registration clinical trial of plazomicin, the Company's lead product candidate being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
As a result of more rapid enrollment than anticipated, Achaogen now expects to release top-line results from the EPIC trial in the first quarter of 2017, two quarters ahead of initial estimates, and plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2017.